LSKL, an inhibitor of Thrombospondin-1 (TSP-1), is a synthetic peptide characterized by its specific sequence that mimics the natural binding sites of TSP-1, a glycoprotein involved in various physiological processes, including angiogenesis and cell adhesion. The trifluoroacetate salt form enhances its solubility and stability in biological systems. This compound is notable for its role in modulating cellular interactions and signaling pathways, particularly in the context of cancer and tissue repair. LSKL has been studied for its potential therapeutic applications, particularly in inhibiting tumor growth and metastasis by disrupting TSP-1's function. The CAS number 2828433-17-4 uniquely identifies this compound, facilitating its recognition in scientific literature and databases. As a peptide, LSKL is expected to exhibit properties typical of such molecules, including susceptibility to enzymatic degradation and a relatively short half-life in vivo. Its efficacy and safety profile are subjects of ongoing research, particularly in the context of targeted therapies in oncology and regenerative medicine.

LSKL, INhibitor of Thrombospondin (TSP-1) trifluoroacetate

2828433-17-4: LSKL, an inhibitor of Thrombospondin-1 (TSP-1), is a synthetic peptide characterized by its specific sequence that mimics the natural binding sites of TSP-1, a glycoprotein involved in various physiological processes, including angiogenesis and cell adhesion. The trifluoroacetate salt form enhances its solubility and stability in biological systems. This compound is notable for its role in modulating cellular interactions and signaling pathways, particularly in the context of cancer and tissue repair. LSKL has been studied for its potential therapeutic applications, particularly in inhibiting tumor growth and metastasis by disrupting TSP-1's function. The CAS number 2828433-17-4 uniquely identifies this compound, facilitating its recognition in scientific literature and databases. As a peptide, LSKL is expected to exhibit properties typical of such molecules, including susceptibility to enzymatic degradation and a relatively short half-life in vivo. Its efficacy and safety profile are subjects of ongoing research, particularly in the context of targeted therapies in oncology and regenerative medicine.

LSKL TFA

LSKL TFA (H-Leu-Ser-Lys-Leu-NH2 TFA) is a TGF-尾1 antagonist that inhibits TSP-1 binding to LAP and reduces renal interstitial fibrosis and liver fibrosis.

CAS 2828433-17-4

LSKL, INhibitor of Thrombospondin (TSP-1) trifluoroacetate

LSKL TFA

Ref: 54-BUP01288

LSKL TFA

Ref: TM-TP2147